Premium
Letter: lipid‐lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B—more evidence is needed. Authors’ reply
Author(s) -
Shaheen A. A.,
AlMattooq M.,
Yazdanfar S.,
Burak K. W.,
Swain M. G.,
Congly S. E.,
Borman M. A.,
Lee S. S.,
Myers R. P.,
Coffin C. S.
Publication year - 2017
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.14282
Subject(s) - tenofovir , medicine , chronic hepatitis , virology , hepatitis b , gastroenterology , virus , human immunodeficiency virus (hiv)